A U.S. judge has ruled Eli Lilly can keep making marketing claims challenged by Novo pending a ruling on a court case brought ...
Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...
Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...
As it continues to confront a potential existential threat in the United States, CRDMO juggernaut WuXi AppTec’s finances ...
The new pact will see Regeneron provide doses of the drug—which includes atoltivimab, maftivimab and odesivimab-ebgn—through 2031. In exchange, the company is in line to receive roughly $270 million ...
Pfizer’s Talzenna is now the first PARP inhibitor approved by the FDA to treat men with metastatic hormone-sensitive prostate ...
As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...
Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September. | In new ...
In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results